摘要
目的:探讨胱抑素C在妇科恶性肿瘤患者早期肾功能损害的评估及预后。方法:在江苏大学附属澳洋医院2022年7月~2023年7月期间随机收取妇科恶性肿瘤患者80例、化疗患者80例、健康妇女80例为研究对象,对比三组患者血中Cys-C、SCr、BUN及CCr的水平。结果:恶性肿瘤组的Cys-C和BUN水平均高于对照组(P < 0.05)。化疗组的血清Cys-C和CCr水平均高于对照组(P < 0.05)。恶性肿瘤组的Cys-C水平与已进行≥5次化疗的患者相比差别有统计学意义(P < 0.05)。在恶性肿瘤组和接受≥5次化疗的患者中,血清中的SCr、Cys-C与CCr水平呈负相关。Cys-C在ROC曲线下面积为0.868,P < 0.05,95%置信区间为(0.794, 0.972)。结论:胱抑素C是反映恶性肿瘤患者早期肾功能损害的准确性指标,且可评定肾功能损伤程度而指导用药。
Objective: To investigate the assessment and prognosis of cystatin C in early renal impairment in patients with gynecological malignancies. Methods: Eighty patients with gynecological malignancies, 80 patients with chemotherapy and 80 healthy women were randomly enrolled in Aoyang Hospital Affiliated to Jiangsu University during July 2022~July 2023, and the blood levels of Cys-C, SCr, BUN and CCr were compared among the three groups. Results: Cys-C and BUN levels were higher in the malignancy group than the control group levels (P < 0.05). Serum Cys-C and CCr levels in the chem-otherapy group were both higher than the levels in the control group (P < 0.05). The difference in serum Cys-C levels in patients with malignant tumours was statistically significant (P < 0.05) com-pared to patients who received more than five cycles of chemotherapy. In the malignancy group and in patients receiving ≥5 chemotherapy, serum levels of SCr, Cys-C and CCr were negatively correlat-ed. The area under the curve for Cys-C was 0.868, P < 0.05, and the 95% confidence interval was (0.794, 0.972). Conclusion: Cystatin C is an accurate indicator of early renal impairment in patients with malignant tumours and can be used to assess the degree of renal impairment and guide drug use.
出处
《临床医学进展》
2023年第11期18430-18435,共6页
Advances in Clinical Medicine
